Exelixis, Inc.
NASDAQ:EXEL · NASDAQ Global Select
+$0.34 today
Vol 5.28M · Avg 2.55M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:EXEL · Revenue to Net Income
Key Ratios
Analysis
$2.4B of revenue converted into $833.4M of net income for the selected period. Gross margin is 96.4% and net margin is 35.1%, showing how much revenue survives after costs and taxes. EPS is $3.02, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3B +7.0% | $2.2B +18.5% | $1.8B +13.6% | $1.6B +12.3% | $1.4B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $83.7M +9.8% | $76.2M +5.1% | $72.5M +25.3% | $57.9M +9.5% | $52.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $2.2B +6.9% | $2.1B +19.0% | $1.8B +13.2% | $1.6B +12.4% | $1.4B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 96.4% -0.1pp | 96.5% +0.4pp | 96.0% -0.4pp | 96.4% +0.1pp | 96.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $825.0M -9.4% | $910.4M -12.8% | $1.0B +17.1% | $891.8M +28.6% | $693.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $518.7M +5.4% | $492.1M -9.3% | $542.7M +18.0% | $459.9M +14.5% | $401.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.4B -8.3% | $1.5B -6.2% | $1.6B +17.4% | $1.4B +23.4% | $1.1B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $29.1M +0.9% | $28.8M +12.0% | $25.7M +23.2% | $20.9M +53.2% | $13.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | $921.8M +28.2% | $718.8M +153.8% | $283.2M +11.0% | $255.2M -17.1% | $307.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 39.7% +6.6pp | 33.1% +17.7pp | 15.5% -0.4pp | 15.8% -5.6pp | 21.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $872.2M +44.3% | $604.6M +253.8% | $170.9M -15.2% | $201.5M -29.7% | $286.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 37.6% +9.7pp | 27.9% +18.5pp | 9.3% -3.2pp | 12.5% -7.5pp | 20.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $69.2M -10.3% | $77.2M -10.8% | $86.5M +161.7% | $33.1M +331.0% | $7.7M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $69.0M -10.4% | $77.0M -11.1% | $86.6M +163.6% | $32.9M +338.9% | $7.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $941.2M +38.1% | $681.6M +164.7% | $257.5M +9.9% | $234.4M -20.3% | $294.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 40.6% +9.1pp | 31.4% +17.4pp | 14.1% -0.5pp | 14.5% -6.0pp | 20.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $158.6M -1.1% | $160.4M +222.3% | $49.8M -4.4% | $52.1M -17.5% | $63.1M | $1.3B | -$1.6B | $745.2M |
| Net Income | $782.6M +50.1% | $521.3M +150.9% | $207.8M +14.0% | $182.3M -21.1% | $231.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | 33.7% +9.7pp | 24.0% +12.7pp | 11.4% +0.0pp | 11.3% -4.8pp | 16.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $3 +60.0% | $2 +176.9% | $1 +14.0% | $1 -21.9% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 +58.0% | $2 +170.8% | $1 +16.1% | $1 -22.2% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $271.6M -6.4% | $290.0M -8.8% | $318.2M -1.0% | $321.5M +2.1% | $314.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $281.9M -4.8% | $296.1M -7.9% | $321.5M -1.0% | $324.6M +0.7% | $322.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$33.54B
Moderna, Inc.
NASDAQ:MRNA
$24.52B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.20B
Align Technology, Inc.
NASDAQ:ALGN
$12.43B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.52B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.63B
Bio-Techne Corporation
NASDAQ:TECH
$8.61B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.13B
Caris Life Sciences, Inc.
NASDAQ:CAI
$5.05B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$213.48M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does EXEL generate?
Exelixis, Inc. (EXEL) reported $2.32B of revenue in fiscal 2025.
Is EXEL profitable?
Exelixis, Inc. (EXEL) reported $782.57M of net income, with a net margin of 33.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.